التفاصيل البيبلوغرافية
| العنوان: |
DataSheet_1_Application of a Novel 68Ga-HER2 Affibody PET/CT Imaging in Breast Cancer Patients.docx |
| المؤلفون: |
Haitao Miao, Yuyun Sun, Yizi Jin, Xichun Hu, Shaoli Song, Jian Zhang |
| سنة النشر: |
2022 |
| المجموعة: |
Frontiers: Figshare |
| مصطلحات موضوعية: |
Cancer, Cancer Cell Biology, Cancer Diagnosis, Cancer Genetics, Cancer Therapy (excl. Chemotherapy and Radiation Therapy), Chemotherapy, Haematological Tumours, Molecular Targets, Radiation Therapy, Solid Tumours, Oncology and Carcinogenesis not elsewhere classified, breast cancer, HER2-positive, PET/CT, 68Ga-HER2 affibody, molecular imaging |
| الوصف: |
Background Breast cancer is a heterogeneous disease, and the human epidermal growth factor receptor 2 (HER2) expression may vary considerably between primary and metastatic lesions, or even within a single lesion. Repeated biopsies cannot always be performed. In this feasibility trial, we assessed whether a novel 68 Ga-NOTA-MAL-MZHER2 ( 68 Ga-HER2) affibody PET/CT could determine the HER2 status of each lesion if there was a clinical need for it. Methods 68 Ga-HER2 affibody PET/CT was performed in breast cancer patients if HER2 status remained unclear after standard examinations (including bone scan, 18 F-FDG PET/CT, CT, and feasible biopsy). All available images for each patient were evaluated through an independent review of two committee-certified radiologists with nuclear medicine expertise. In case of discrepancy, adjudication by a third radiologist was performed as needed. All radiologists were blinded to the clinical information. Results Twenty-four patients were enrolled. 68 Ga-HER2 affibody PET/CT was requested by physicians due to the following reasons: 6 with multiple primary cancers, 13 with metastases not amenable to biopsy or repeated biopsy, 6 with inconsistent HER2 status between primary and metastatic lesions, and 4 with different HER2 status within different metastases. The final PET report revealed that the 68 Ga-HER2 affibody tumor uptake was considered positive in 16 patients, negative in 7 patients, and equivocal in one patient. The heterogeneity of 68 Ga-HER2 affibody uptake was observed, with a maximal 8.5-fold difference within one patient and a maximal 11-fold difference between patients. 68 Ga-HER2 affibody PET/CT demonstrated a high diagnostic accuracy in differentiating HER2-enriched breast cancer, with a sensitivity of 91.7% and a specificity of 84.6%, regardless of prior lines of anti-HER2 therapies. Conclusion 68 Ga-HER2 affibody PET/CT imaging could provide valuable information on HER2 expression of each tumor in the body of patients, which may help in personalized clinical ... |
| نوع الوثيقة: |
dataset |
| اللغة: |
unknown |
| العلاقة: |
https://figshare.com/articles/dataset/DataSheet_1_Application_of_a_Novel_68Ga-HER2_Affibody_PET_CT_Imaging_in_Breast_Cancer_Patients_docx/19938179Test |
| DOI: |
10.3389/fonc.2022.894767.s001 |
| الإتاحة: |
https://doi.org/10.3389/fonc.2022.894767.s001Test
https://figshare.com/articles/dataset/DataSheet_1_Application_of_a_Novel_68Ga-HER2_Affibody_PET_CT_Imaging_in_Breast_Cancer_Patients_docx/19938179Test |
| حقوق: |
CC BY 4.0 |
| رقم الانضمام: |
edsbas.F1661FE4 |
| قاعدة البيانات: |
BASE |
